California Stem Cell, Inc. Release: Cancer Immunotherapy Platform Targets Broad Range of Metastatic Cancers

Published: Jul 31, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

IRVINE, Calif.--(BUSINESS WIRE)--California Stem Cell, Inc. (CSC) has announced the completion of an internal study demonstrating that the company’s proprietary immunotherapy manufacturing process can be applied to multiple cancer types. Originally developed for late stage metastatic melanoma, the platform tissue culture technology has also been shown to work with tumor tissues from hepatocellular carcinoma, ovarian cancer, glioblastoma multiforme, and other solid tumor cancers.

Help employers find you! Check out all the jobs and post your resume.

Back to news